Celcuity Inc
CELC38.500USD
+1.710+4.65%
收盤 07/29, 16:00（美東）報價延遲15分鐘
1.46B總市值
虧損本益比TTM
關於 Celcuity Inc 公司
Celcuity Inc. 是一家臨牀階段的生物技術公司，開發用於治療多種實體腫瘤的靶向療法。其主要治療候選藥物是 gedatolisib，這是一種強效的小分子可逆抑制劑，可選擇性靶向所有 I 類磷脂酰肌醇-3-激酶 (PI3K) 亞型和兩種雷帕黴素靶標 (mTOR) 亞複合物 mTORC1 和 mTORC2。其針對 gedatolisib 的初始臨牀開發計劃專注於治療激素受體陽性 (HR+)、人表皮生長因子受體 2 陰性 (HER2-) 或 HR+/HER2-、晚期或轉移性乳腺癌患者以及轉移性去勢抵抗性前列腺癌患者。其 VIKTORIA-1 正在評估 gedatolisib 與氟維司羣聯合使用或不聯合使用哌柏西利對 HR+/HER2- 晚期乳腺癌患者的療效。其 CELsignia 伴隨診斷平臺能夠分析活體患者腫瘤細胞，以識別新的癌症患者羣體。
公司簡介
公司代碼CELC
公司名稱Celcuity Inc
上市日期Sep 20, 2017
成立日期2017
CEOMr. Brian F. Sullivan
員工數量87
證券類型Ordinary Share
年結日Sep 20
公司地址16305 36th Ave N Ste 100
城市MINNEAPOLIS
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編55446-4285
電話17633920767
網址https://www.celcuity.com/
公司代碼CELC
上市日期Sep 20, 2017
成立日期2017
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
股東類型
持股股東
佔比
Hedge Fund
37.76%
Investment Advisor
19.79%
Individual Investor
12.29%
Investment Advisor/Hedge Fund
10.89%
Private Equity
6.29%
Venture Capital
4.91%
Research Firm
1.98%
Corporation
0.92%
Pension Fund
0.09%
Other
5.09%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
212
36.06M
95.24%
-3.88M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1%
iShares Genomics Immunology and Healthcare ETF
0.93%
ALPS Medical Breakthroughs ETF
0.37%
Tema Oncology ETF
0.26%
iShares Micro-Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.02%
iShares Russell 2000 ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1%
iShares Genomics Immunology and Healthcare ETF
佔比0.93%
ALPS Medical Breakthroughs ETF
佔比0.37%
Tema Oncology ETF
佔比0.26%
iShares Micro-Cap ETF
佔比0.08%
iShares Russell 2000 Growth ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
